Abstract
Ischemic stroke is responsible for about one third of all deaths in industrialized countries and is the major cause of serious, long-term disability in adults over the age of 45. It stands to reason that there is a need for pharmacotherapy to treat acute ischemic stroke. In over two decades of research, the hope of developing a neuroprotective drug that effectively reduces the severity of damage after stroke has not been realized. However, considerable insights have been gained into the mechanisms and cascade of events that occurs following stroke as well as an improved understanding of neuronal injury and cell death. Recent studies in humans indicate many parallels with animal studies not only in the nature of events following ischemia, but also in their time course. Multiple pathways are known to be involved and yet the majority of treatments are still being designed to target a single effector in these pathways. Combinations of drugs, or drugs, which have multiple actions, targeting several pathways may prove to be a more successful strategy.
Keywords: stroke, neuroprotection, combination therapy, hybrid drugs, antioxidants, pharmacotherapy
Current Neuropharmacology
Title: Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants
Volume: 2 Issue: 3
Author(s): Jennifer K. Callaway
Affiliation:
Keywords: stroke, neuroprotection, combination therapy, hybrid drugs, antioxidants, pharmacotherapy
Abstract: Ischemic stroke is responsible for about one third of all deaths in industrialized countries and is the major cause of serious, long-term disability in adults over the age of 45. It stands to reason that there is a need for pharmacotherapy to treat acute ischemic stroke. In over two decades of research, the hope of developing a neuroprotective drug that effectively reduces the severity of damage after stroke has not been realized. However, considerable insights have been gained into the mechanisms and cascade of events that occurs following stroke as well as an improved understanding of neuronal injury and cell death. Recent studies in humans indicate many parallels with animal studies not only in the nature of events following ischemia, but also in their time course. Multiple pathways are known to be involved and yet the majority of treatments are still being designed to target a single effector in these pathways. Combinations of drugs, or drugs, which have multiple actions, targeting several pathways may prove to be a more successful strategy.
Export Options
About this article
Cite this article as:
Callaway K. Jennifer, Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359602
DOI https://dx.doi.org/10.2174/1570159043359602 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SARS: Understanding the Virus and Development of Rational Therapy
Current Molecular Medicine Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Blood Pressure Variability and Mortality in end Stage Renal Disease
Current Hypertension Reviews CD133 Expressing Pericytes and Relationship to SDF-1 and CXCR4 in Spinal Cord Injury
Current Neurovascular Research Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Nitric Oxide is a Central Common Metabolite in Vascular Dysfunction Associated with Diseases of Human Pregnancy
Current Vascular Pharmacology CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues
Current Alzheimer Research Human Recombinant Leptin Administration as a Potential Obesity Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Cardiovascular Disease and Dyslipidemia: Beyond LDL
Current Pharmaceutical Design MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry Cytoprotective and Antiproliferative Effects of HMG-CoA Reductase Inhibitors
Current Enzyme Inhibition Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk
Current Vascular Pharmacology A Review on Experimental Methods for Diabetes Induction and Therapeutic Efficacy of Anti-diabetic Drug Loaded Nanoformulation
Current Drug Therapy Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus
Current Medicinal Chemistry